DK2300514T3 - Fremgangsmåde til syntetisering af en hovedsagelig monodispergeret blanding af oligomere - Google Patents
Fremgangsmåde til syntetisering af en hovedsagelig monodispergeret blanding af oligomere Download PDFInfo
- Publication number
- DK2300514T3 DK2300514T3 DK08808172.4T DK08808172T DK2300514T3 DK 2300514 T3 DK2300514 T3 DK 2300514T3 DK 08808172 T DK08808172 T DK 08808172T DK 2300514 T3 DK2300514 T3 DK 2300514T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- acid
- compound
- sodium
- temperature
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 35
- 239000000203 mixture Substances 0.000 title claims description 23
- 230000002194 synthesizing effect Effects 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 16
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 11
- 125000003827 glycol group Chemical group 0.000 claims description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000000010 aprotic solvent Substances 0.000 claims description 10
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 6
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 claims description 6
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims description 6
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 5
- 235000011149 sulphuric acid Nutrition 0.000 claims description 5
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 4
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 3
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ZMCJTXKSDDFJRG-UHFFFAOYSA-N 3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propanoic acid Chemical compound COCCOCCOCCOCCC(O)=O ZMCJTXKSDDFJRG-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- MAYFFZZPEREGBQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propanoate Chemical compound COCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O MAYFFZZPEREGBQ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- -1 monocydohexylamine Chemical compound 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- JUINYDFUOXIVCX-UHFFFAOYSA-N tert-butyl 3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propanoate Chemical compound COCCOCCOCCOCCC(=O)OC(C)(C)C JUINYDFUOXIVCX-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
- C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Claims (11)
1. Fremgangsmåde til syntetisering af en i det væsentlige monodispergeret blanding af oligomere, omfattende polyetylenglykoldele af forbindelse repræsenteret ved Formula IV, hvilken fremgangsmåde omfatter trinene: a. reagering af en i det væsentlige monodispergeret blanding af forbindelser med strukturen af Formula I _FORMULA I
hvori R1 er en lavere eller højere alkyl, n= 1 til 20, og X+ er en positiv ion med tertbutylacrylat under tilstedeværelse af en base under betingelser, som er tilstrækkelige til at tilvejebringe en forbindelse med Formula II
FORMULA II hvori R1 er en lavere eller højere alkyl, n= 1 til 20; b. konvertering af forbindelsen af Formula II til en forbindelse af Formula III under tilstedeværelse af en syre og vand, hvori syren er valgt fra en gruppe bestående af p-toluensulfonsyre (PTSA), pyridinium p-toluensulfonat (PPTS), trifluo-reddikesyre (TFA), metansulfonsyre (MeS03H), etansulfonsyre (EtS03H), benzen-sulfonsyre (PhS03H), og svovlsyre (H2S04)
FORMULA ΙΠ hvori R1 er en lavere eller højere alkyl, n= 1 til 20; og c. opløsning af forbindelsen af Formula III i et aprotisk opløsningsmiddel og tilsætning af thionylklorid ved en temperatur fra 0 til 40°C til dannelse af et syreklorid og aktivering af syrekloridet under tilstedeværelse af N-hydroxysuccinimid og en alifatisk amin valgt fra gruppen bestående af monometylamin, dimetylamin, trimetylamin, monoetylamin, dietylamin, trietylamin, monoisopropylamin, diiso-propylamin, mono-n-butylamin, di-n-butylamin, tri-n-butylamin, monocyclohe-xylamin, dicyclohexylamin og blandinger deraf, for at opnå forbindelsen af Formula IV
FORMULA IV
2. Fremgangsmåde ifølge krav 1, hvori trin (a) udføres ved en temperatur på 0°C til 40°C.
3. Fremgangsmåde ifølge krav 2, hvori trin (a) udføres ved en temperatur på ca. 25 °C.
4. Fremgangsmåde ifølge krav 1, hvori basen anvendt i trin (a) er valgt fra gruppen bestående af natriummetoxid, natriumetoxid (NaOEt), natriummetal (Na-metal), natriumhydroxid (NaOFI), kaliumhydroxid (KOFI), lithiumhydroxid (LiOH), natriumhydrid (NaFI), kalciumhydroxid (Ca(OFI)2), natriumkarbonat (Na2C03) og bariumhydroxid (Ba(OFI)2).
5. Fremgangsmåde ifølge krav 4, hvori basen anvendt i trin (a) is natriummetoxid.
6. Fremgangsmåde ifølge krav 1, hvori trin (b) udføres ved en temperatur på 0°C til 80°C.
7. Fremgangsmåde ifølge krav 6, hvori trin (b) udføres ved en temperatur på ca. 80°C.
8. Fremgangsmåde ifølge krav 1, hvori det aprotiske opløsningsmiddel anvendt i trin (c) er valgt fra gruppen bestående af Ν,Ν-dimetylacetamid (DMA), N,N-dimetylformamid (DMF), dimetylsulfoxid, hexametylfosfortriamid, tetrahydrofuran (TFIF), dioxan, dietylæter, metyl-t-butylæter (MTBE), toluen, benzen, hexan, pen-tan, N-metylpyrollidinon, diklorometan, kloroform, tetrahydronaphthalen, decahy-dronaphthalen, 1,2-diklorobenzen, 1,3-dimetyl-2-imidazolidinon, og en blanding deraf.
9. Fremgangsmåde ifølge krav 8, hvori det aprotiske opløsningsmiddel er N,N-dimetylformamid.
10. Fremgangsmåde ifølge krav 1, hvori trin (c) yderligere omfatter kombinering af N-hydroxysuccinimid i metylenklorid og afkøling til en temperatur fra 0 til 5°C og derefter tilsætning af den alifatiske am in.
11. Fremgangsmåde ifølge krav 1, hvori den alifatiske amin er trietylamin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1694CH2008 | 2008-07-14 | ||
| PCT/IN2008/000545 WO2010007626A1 (en) | 2008-07-14 | 2008-08-28 | A method of synthesizing a substantially monodispersed mixture of oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2300514T3 true DK2300514T3 (da) | 2016-06-27 |
Family
ID=41550060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08808172.4T DK2300514T3 (da) | 2008-07-14 | 2008-08-28 | Fremgangsmåde til syntetisering af en hovedsagelig monodispergeret blanding af oligomere |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9040723B2 (da) |
| EP (1) | EP2300514B1 (da) |
| JP (1) | JP5480257B2 (da) |
| KR (1) | KR101311597B1 (da) |
| CN (1) | CN102099397B (da) |
| BR (1) | BRPI0823084B1 (da) |
| DK (1) | DK2300514T3 (da) |
| ES (1) | ES2572891T3 (da) |
| IL (1) | IL210598A (da) |
| MY (1) | MY155612A (da) |
| PL (1) | PL2300514T3 (da) |
| PT (1) | PT2300514E (da) |
| WO (1) | WO2010007626A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013513622A (ja) | 2009-12-14 | 2013-04-22 | ユニバーシティ オブ マサチューセッツ | 白内障及び老眼を阻害する方法 |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| JP6397477B2 (ja) * | 2013-03-14 | 2018-09-26 | ザ ユニバーシティ オブ マサチューセッツＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 白内障及び老眼を阻害する方法 |
| EP3373921B1 (en) * | 2015-11-13 | 2019-08-28 | The University of Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CN109179838A (zh) * | 2018-10-11 | 2019-01-11 | 凯莱英生命科学技术(天津)有限公司 | 含三乙胺的dmf废水的处理方法 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU575038B2 (en) * | 1983-01-28 | 1988-07-21 | Fujisawa Pharmaceutical Co., Ltd. | Aminoglycoside derivatives, eg 2'n-palmitoyl-kasugamycin |
| US4980482A (en) * | 1988-01-19 | 1990-12-25 | The Dow Chemical Company | Process for the preparation of N-maleoyl activated esters of amino acids |
| ES2247656T3 (es) * | 1989-04-19 | 2006-03-01 | Enzon, Inc. | Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno. |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| EP1507755A4 (en) | 2001-12-11 | 2006-05-17 | Sun Bio Inc | NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES |
| KR20050115251A (ko) * | 2003-02-28 | 2005-12-07 | 알자 코포레이션 | 리포좀-유도된 보체의 활성화를 감소시키기 위한 리포좀조성물 |
| CA2521648C (en) * | 2003-04-17 | 2012-07-03 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| WO2005025498A2 (en) | 2003-09-08 | 2005-03-24 | Corus Pharma | Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation |
| CA2553528C (en) * | 2004-01-21 | 2012-12-04 | Nektar Therapeutics Al, Corporation | Method of preparing propionic acid-terminated polymers |
| CA2910494C (en) * | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
-
2008
- 2008-08-28 EP EP08808172.4A patent/EP2300514B1/en active Active
- 2008-08-28 PT PT08808172T patent/PT2300514E/pt unknown
- 2008-08-28 DK DK08808172.4T patent/DK2300514T3/da active
- 2008-08-28 JP JP2011518060A patent/JP5480257B2/ja not_active Expired - Fee Related
- 2008-08-28 MY MYPI2011000187A patent/MY155612A/en unknown
- 2008-08-28 US US13/054,418 patent/US9040723B2/en active Active
- 2008-08-28 CN CN2008801303593A patent/CN102099397B/zh not_active Expired - Fee Related
- 2008-08-28 BR BRPI0823084-6A patent/BRPI0823084B1/pt not_active IP Right Cessation
- 2008-08-28 PL PL08808172.4T patent/PL2300514T3/pl unknown
- 2008-08-28 ES ES08808172.4T patent/ES2572891T3/es active Active
- 2008-08-28 KR KR1020117003255A patent/KR101311597B1/ko not_active Expired - Fee Related
- 2008-08-28 WO PCT/IN2008/000545 patent/WO2010007626A1/en not_active Ceased
-
2011
- 2011-01-12 IL IL210598A patent/IL210598A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110040916A (ko) | 2011-04-20 |
| JP2011528032A (ja) | 2011-11-10 |
| US9040723B2 (en) | 2015-05-26 |
| HK1156335A1 (zh) | 2012-06-08 |
| EP2300514A4 (en) | 2012-12-12 |
| EP2300514A1 (en) | 2011-03-30 |
| EP2300514B1 (en) | 2016-03-23 |
| CN102099397A (zh) | 2011-06-15 |
| WO2010007626A1 (en) | 2010-01-21 |
| IL210598A0 (en) | 2011-03-31 |
| KR101311597B1 (ko) | 2013-09-26 |
| IL210598A (en) | 2014-06-30 |
| PT2300514E (pt) | 2016-06-20 |
| MY155612A (en) | 2015-11-13 |
| US20110118480A1 (en) | 2011-05-19 |
| PL2300514T3 (pl) | 2016-09-30 |
| ES2572891T3 (es) | 2016-06-02 |
| BRPI0823084A2 (pt) | 2015-06-16 |
| CN102099397B (zh) | 2012-12-12 |
| JP5480257B2 (ja) | 2014-04-23 |
| BRPI0823084B1 (pt) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2300514T3 (da) | Fremgangsmåde til syntetisering af en hovedsagelig monodispergeret blanding af oligomere | |
| ES2532377T3 (es) | Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida | |
| US8227628B2 (en) | Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein | |
| CN107235895A (zh) | 制备取代的5‑甲氧基甲基吡啶‑2,3‑二甲酸衍生物的方法 | |
| CN105037237B (zh) | 合成n‑马来酰亚胺基烷基酸及其琥珀酰亚胺酯的方法 | |
| TWI871182B (zh) | 用於fapi合成的中間體及其製備方法和應用 | |
| CN118271255A (zh) | 一种多替诺德的制备方法 | |
| EP2170821B1 (en) | Method for preparing fmoc-based hydrolysable linkers | |
| CN110475801B (zh) | 在末端具有多个羟基的聚氧乙烯衍生物的制造方法 | |
| CN118271256A (zh) | 一种多替诺德的合成方法 | |
| WO2023143374A1 (zh) | 一种配体、其制备方法及应用 | |
| HK1156335B (en) | A method of synthesizing a substantially monodispersed mixture of oligomers | |
| CN113200919A (zh) | 一种n-乙酰-肌肽的合成方法 | |
| CN109988121A (zh) | 一种阿考替胺衍生物的制备方法 | |
| HK1156059A (en) | A method of synthesizing a substantially monodispersed mixture of oligomers | |
| CN100420671C (zh) | 一种马来酰亚胺衍生物及其制备方法与应用 | |
| WO2021185304A1 (zh) | 制备长脂肪链二酸衍生物的方法及其应用 | |
| CN101003487B (zh) | 1,3-双(3-氨基苯氧基)苯的制备方法 | |
| KR100696187B1 (ko) | 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법 | |
| CN120172957A (zh) | 一种托吡司特中间体的制备方法 | |
| CN109384734A (zh) | 一种塞尔西帕中间体的制备方法 | |
| DK164050B (da) | 4-benzyloxy-3-pyrrolin-2-on samt anvendelse deraf til fremstilling af tetramsyre | |
| KR20010024790A (ko) | 이소프로필-메틸-[2-(3-ｎ-프로폭시페녹시)에틸]아민의제조 방법 | |
| TW202124408A (zh) | 胜肽化合物之製造方法、保護基形成用試劑及肼衍生物 | |
| JPS6089454A (ja) | １，３−ビス（３−アミノフエノキシ）−５−ハロゲノベンゼンおよびその製造方法 |